Long-term collaboration with Professor Shaomeng Wang’s lab at the University of Michigan
R&D team of 40+ scientists
US$4-5MM research funding annually
15+ years academic research experience
R&D team with 10+ years experience with US standard
The team licensed out two apoptosis-targeted assets to big pharma with a total deal size exceeding $600MM
Complete R&D functions including CMC, preclinical and clinical development
Global quality R&D data
1. National 863 “New Therapeutic Target Research” Project and “Drug Design” sub-project. Among all applications, Ascentage Pharma is the only company chosen to participate in these projects.
2. National “Major New Drug Development” Key Project - “Enterprise Innovative Drugs Development Incubator” Program. Ascentage Pharma ranked third among more than 50 participants nationwide.
3. Jiangsu Province Science and Technology Innovation Team; Jiangsu Provincial Key Laboratory.
4. “Key Chinese Entrepreneurial Team” Project supported by the Overseas Chinese Affairs Office of the State Council of China.